Senvelgo is a drug owned by BOEHRINGER LNGELHEIM ANIMAL HEALTH USA, INC. It is protected by 8 US drug patents filed from 2027 to 2038. All patents are active. Details of Senvelgo’s patents and their expiration are given below.
| Drug Patent Number | Drug Patent Expiry | Status |
|---|---|---|
 | ||
| US10709683 | 24 Aug, 2036 | Active |
| US10617666 | 06 Jun, 2035 | Active |
| US11896574 | 17 Dec, 2034 | Active |
| US9145434 | 07 Sep, 2033 | Active |
| US7776830 | 01 May, 2027 | Active |
| US8557782 | 01 May, 2027 | Active |
Exclusivity Information
Senvelgo holds 1 exclusivity out of which 0 have expired. Its last outstanding exclusivity is set to expire in 2028. Details of Senvelgo's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| NCE | Aug 10, 2028 |
About Senvelgo
Senvelgo is a drug
owned by BOEHRINGER LNGELHEIM ANIMAL HEALTH USA, INC.
Senvelgo uses
Velagliflozin as the active
ingredient.
Active Ingredient:
Senvelgo uses
Velagliflozin as the active ingredient.
Check out other Drugs and Companies using
Velagliflozin ingredient.